Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Inclusion Criteria

• Phase 1b only: B-cell non-Hodgkin's lymphoma (NHL), relapsed or refractory to standard approved therapies
• DLBCL Phase 2 cohort: De novo or transformed diffuse large B-cell lymphoma (DLBCL) expressing cluster of differentiation (CD) 20, relapsed or refractory to at least 2 prior lines treatment containing anti-CD20 therapy
• Indolent lymphoma Phase 2 cohort: Marginal zone or follicular lymphoma, relapsed or refractory to standard approved therapies
• DLBCL chemotherapy combination cohort: De novo or transformed diffuse large B-cell lymphoma (DLBCL), relapsed or refractory to 1-3 prior lines of treatment
• Adequate performance status and hematological, liver and kidney functions
• Willing to consent to 1 mandatory pre-treatment and 1 on-treatment tumor biopsy Key

Exclusion Criteria

• Active brain metastases
• Prior allogeneic hematopoietic cell transplantation
• Prior treatment with CD47 or signal regulatory protein alpha (SIRPα) targeting agents
• Second malignancy within the last 3 years
• Known active or chronic hepatitis B or C infection or HIV
• Pregnancy or active breastfeeding
• Prior chimeric antigen receptor (CAR-T) therapy Note: Other protocol defined Inclusion/Exclusion criteria may apply.